Winter 2026 Canadian Cancer Survivor Network Survey for Patient and Caregiver Input on New Treatments for Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
The pan-Canadian Oncology Drug Review invites patient groups to prepare and send in submissions so that patients and caregivers like you can be heard. Please join us and have your voice included in this important submission process. All information provided will remain anonymous when used in the submission.
The purpose of this survey is to provide the Canadian Cancer Survivor Network with insights and perspectives about living with and managing platinum-resistant recurrent ovarian cancer (both PD-L1 positive and negative) from patients and caregivers in order to complete a patient evidence submission for new treatments that are under review in Canada.
The following indication is being considered for reimbursement:
Pembrolizumab (Keytruda), in combination with paclitaxel, with or without bevacizumab, for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumours express PD-L1 with a combined positive score greater or equal to 1 (CPS≥1)* as determined by a validated test, and who have received one or two prior systemic treatment regimens.
If you are a patient outside of this specification and feel you may also benefit from this treatment, we would like to hear from you as well. Your input could help inform what is desired from patients and caregivers in new and upcoming medications and treatments.
This survey should take approximately 5-10 minutes to complete and will remain open until Thursday March 12, 2026.
Thank you for your participation!
*If a tumour is producing a lot of the PD-L1 protein, it is a sign (aka biomarker) that the tumour is actively working to hide itself from the immune system and is likely growing unchecked.
The purpose of this survey is to provide the Canadian Cancer Survivor Network with insights and perspectives about living with and managing platinum-resistant recurrent ovarian cancer (both PD-L1 positive and negative) from patients and caregivers in order to complete a patient evidence submission for new treatments that are under review in Canada.
The following indication is being considered for reimbursement:
Pembrolizumab (Keytruda), in combination with paclitaxel, with or without bevacizumab, for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumours express PD-L1 with a combined positive score greater or equal to 1 (CPS≥1)* as determined by a validated test, and who have received one or two prior systemic treatment regimens.
If you are a patient outside of this specification and feel you may also benefit from this treatment, we would like to hear from you as well. Your input could help inform what is desired from patients and caregivers in new and upcoming medications and treatments.
This survey should take approximately 5-10 minutes to complete and will remain open until Thursday March 12, 2026.
Thank you for your participation!
*If a tumour is producing a lot of the PD-L1 protein, it is a sign (aka biomarker) that the tumour is actively working to hide itself from the immune system and is likely growing unchecked.